Center for Vaccine Research
Center for Vaccine Research consists of Department of Infectious Immunology, Vaccine Development and QA/QC. The Center is unique in its composition as it includes not only a basic and translational research department but also GMP facilities, animal testing facilities and has expertise that enables accelerated development of new vaccines targeted at regional infection threats.
Center for Vaccine Research
Peter L. Andersen is Executive Vice President, Center for Vaccine Research (CVR) at Statens Serum Institut. In his current position, he is responsible for the overall coordination of vaccine research and development covering activities from early research to clinical development. His research has been focused on the identification and characterisation of antigens, immune mechanisms and vaccine delivery systems that mediate protection against important pathogens such as Mycobacterium tuberculosis, Chlamydia trachomatis, Streptococcus pyogenes and Influenza. He has pioneered work on TB and Chlamydia vaccines, the CAF series of liposomal adjuvants and novel TB diagnostic assays and reagents.
The program in CVR currently has two TB vaccines in late stage clinical testing and different liposomal adjuvant formulations and a novel Chlamydia trachomatis vaccine in phase 1 trials. The program also has a number of advanced novel and innovative vaccine modalities in late stage preclinical evaluation. In collaboration with industrial partners, his team has developed novel TB diagnostic tests (the IGRA assays) that are in widespread worldwide clinical use today and has recently completed a large-scale phase 3 testing of a novel specific skin test reagent to substitute for tuberculin.
Peter Andersen has an extensive scientific production of more than 350 papers (Google Scolar H-index 99, WoW H-index 77), over 20 patents and has given lectures all over the world. He was recognized by Thomson Scientific as the most cited researcher in Denmark within the field of immunology (1990 to 2005), and as one of the most cited researchers in the world within the diverse field of Tuberculosis (2009). Peter Andersen heads several international research consortiums (see list below), has organized and chaired many international meetings, and received numerous large national and international research grants. He has received several prizes and awards and in 2011 he received the Novo Nordisk Prize; the most prestigious Danish award given as an acknowledgement for a lifetime scientific achievement. Peter Andersen is a member of the Danish Research Council.
POR TB Consortium
Title: POR TB Consortium; Phase 2 trial to determine efficacy of the multistage vaccine H56:IC31 for Prevention of Recurrent TB disease
Objective: The project aims 1) to accelerate the clinical development of the leading TB vaccine candidate (H56:IC31) by conducting a phase 2 prevention of recurrent TB vaccine trial 2) to support capacity Development to expand TB vaccine clinical trial and Laboratory expertise in Sub-saharan Africa 3) to advance understanding of mechanisms of reactogenisity, immunogenicity and efficacy
Participants: The Aurum Institute, South Africa; Ospedale San Raffaele, Italy; University of Cape Town, SATVI, South Africa; Task Foundation NPC, South Africa; University of Cape Town, Lung Institute, South Africa; National Institute of Medical Research - Tanzania (NIMR); Areas Global Tuberculosis Foundation NPC, South Africa and Statens Serum Institut (SSI), Denmark
Funded by: The European & Developing Countries Clinical Trials Partnership (EDCTP)
A dual function TB subunit vaccine
Title: A dual function TB subunit vaccine designed for non-interference with BCG and post-exposure activity
Objective: The project aims to perform molecular modifications of a family of new vaccine candidates in order to enhance immunogenicity in vivo in preventive and post-exposure settings. Further the project will evaluate the modified vaccines in multiple novel advanced animal models of post-Mtb exposure and develop a GMP product towards clinical trial progression of the best vaccine candidate.
Participants: Staten Serum Institut (SSI,Denmark), Center for Infectious Disease Research (CIDR, USA), Public Health England (PHE)
Funded by: National Institutes of Health (NIH), USA
Contact: Rasmus Skaarup Morten, email@example.com
Title: Developing a Chlamydia Trachomatis vaccine
Objective: The TracVac consortium works towards eliminating the global problem of blinding trachoma through the development of a vaccine. TracVac has two main objectives. The first main objective is to generate a vaccine that protects against the bacterial strains causing ocular Chlamydia trachomatis infections. The second objective is to develop an immunization protocol for optimal mucosal immunity. Read more at www.trachoma-vaccine.org
Participants: TracVac is an European consortium consisting of 4 partners, Statens Serum Institut 8DK), Imperial College (UK), London School og Hygiene & Tropical Medicine (UK) and The French Alternative Engergies and Atomic Energy, CEA (France)
Funded by: European Union, H2020
Contact: Frank Follmann, firstname.lastname@example.org
Title: Personalized cancer immunotherapy using adjuvanted Neo-epitope Peptide based Vaccines
Objective: The overall aim of the project is to generate personalized immune therapy vaccines that are likely to be highly efficacious in a large fraction of cancer patients and strengthen the effect of check-point inhibitors. The four specific objectives are: to develop personalized cancer vaccines based on peptides in combination with the CAF09b adjuvant designed to provide optimal immunotherapy through CTL induction to complete a phase l trial with neoepitope based immunotherapy in cancer patients and provide PoC for the overall strategy, safety and clinical feasibility improve prediction algorithms, through identification of neoepitopes using syngenic mouse models and in-depth analyses of immune reactivity in vaccinated patients to develop vaccine delivery strategies to broaden the neoepitope repertoire and increase the response and efficacy of the vaccine.
Participants: NeoPepVac is a Danish consortium comprising 4 partners, Statens Serum Institut, Evaxion Biotech, Technical University of Denmark and Herlev Hospital
Funded by: Innovation Fund Denmark
Contact: Dennis Christensen, email@example.com
Title: European Vaccine Research and Development Infrastructure
Objective: The objective of the Transvac2 consortium is to further advance the establishment of a fully operational and sustainable European vaccine R&D infrastructure. TransVac2 will support innovation for both prophylactic and terapeutic vaccine development based on a disease-overarching and one-health approach, thereby optimizing the knowledge and expertise gained during the development of both human and animal vaccines. Read more at www.transvac.org
Participants: TransVac2 is a European consortium comprising a comprehensive collection of 26 leading European institutions.
Funded by:European Union H2020
Contact: Dennis Christensen, firstname.lastname@example.org Anders Bæk Vestermark, email@example.com
Title: Advancing novel and promising TB vaccine candidates from discovery to preclinical and early clinical development
Objective: TBVAC2020 aims to innovate and diversify the current TB vaccine and biomarker pipeline while at the same time develop new tools that allow us to select as early as possible the most promising TB vaccine candidates, and accelerate their development. TBVAC2020 proposes to achieve this by combining research activities e.g. vaccine discorvery, new preclinical models addressing clinical challenges and identification and characterisation of correlates of protection with head-to-head comparative preclinical and clinical evaluation. Read more at www.tbvi.eu/for-partners/tbvac2020/
Participants: TBVAC2020 is an international consortium consisting 40 partners from Europa, Asia, Africa and Australia
Funded by: Eurpean Union H2020
Eliciting lung-localized CD4 T cell responses against Mtb
Title: Eliciting lung-localized CD4 T cell responses against Mycobacterium tuberculosis in preventive and post-exposure settings
Objective: The project aims to elucidate basic mechanisms for how CD4 T cells can migrate into the lung tissue, how they are positioned relative to the infected areas (granulomas) and how they can be retained once there as well as be refractory to functional exhaustion during the chronic / latent phase of the infection. In addition, the project aims to develop vaccination strategies that optimally prime such protective CD4 T cells, regardless of previous exposure status to Mtb.
Participants: Center for Infectious Disease Research (CIDR) USA, Statens Serum Institut (SSI) Denmark University of Cape Town/SATVI, South Africa
Funded by: National Institutes of Health (NIH), USA